COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 288,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES (IFRS)

€ in millions | H1/19 | H1/18 | Change | FY/18
--- | --- | --- | --- | ---
Sales and Earnings | | | | |
Sales | 17,296 | 15,994 | 8% | 33,009
EBIT | 2,192 | 2,185 | 0% | 4,547
Net income | 945 | 924 | 2% | 1,872
Earnings per ord. share in € | 1,70 | 1,66 | 2% | 3.37
Balance sheet and cash flow | | | | |
Total assets | 59,342 | 56,703 | 5% | 105,861
Non-current assets | 44,491 | 41,913 | 6% | 86,364
Equity | 25,568 | 25,008 | 2% | 50,176
Equity ratio | 43% | - | -- | 44%
Net debt/EBITDA |  |  | -- | 2.71
Investments | 3,163 | 1,217 | -9% | 3,249
Operating cash flow | 1,141 | 1,256 | -9% | 3,742
Operating cash flow in % of sales | 6.6% | 7.6% | -- | 11.2%
Profitability | | | | |
EBIT margin | 12.7% | 13.7% | -- | 13.8%
Return on equity after taxes (ROE) | 11.9% | 12.7% | -- | 12.1%
Return on operating assets (ROOA) | 8.4% | 9.0% | -- | 9.0%
Return on invested capital (ROIC) | 7.5% | 8.2% | -- | 8.3%
Employees | 288,459 | 276,750 | 4% | 565,200

1. On a comparable basis
2. Net income attributable to shareholders of Fresenius SE & Co. KGaA
3. Including noncontrolling interest
4. Before special items; adjusted for IFRS 16 effect
5. At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures
6. Investments in property, plant and equipment, acquisitions
7. Adjusted for IFRS 16 effect
8. As of June 30, 2019

BUSINESS SEGMENTS (IFRS)

€ in millions | H1/19 | H1/18 | Change | FY/18
--- | --- | --- | --- | ---
Fresenius Medical Care | Sales | 8,409 | 7,680 | 9% | 16,026
EBIT | 1,042 | 1,064 | -2% | 2,292
Fresenius Kabi | Sales | 3,392 | 3,207 | 6% | 6,544
EBIT | 611 | 557 | 10% | 1,139
Fresenius Helios | Sales | 4,660 | 4,674 | 0% | 8,993
EBIT | 540 | 571 | -5% | 1,052
Fresenius Vamed | Sales | 907 | 515 | 76% | 1,688
EBIT | 31 | 18 | 72% | 110

1. On an adjusted basis: before special items, adjusted for IFRS 16 effect, excluding effects from NxStage transaction
2. 2018 adjusted for divestitures of Care Coordination activities
3. On a comparable basis, before special items and adjusted for IFRS 16 effect
4. H1/19 adjusted for IFRS 16 effect

Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases. As of June 30, 2019, Fresenius Medical Care was treating 339,550 patients in 3,996 dialysis clinics. Along with its core business, the company provides related medical services in the field of Care Coordination.

Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.

Fresenius Helios Fresenius Helios is Europe’s leading private hospital operator. Helios Germany operates 86 hospitals, ~125 outpatient centers and treats approximately 5.3 million patients annually. Quirónsalud operates 50 hospitals, 62 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 13.3 million patients annually.

Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe.

SALES BY REGION

<table>
<thead>
<tr>
<th>Region</th>
<th>Sales Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America</td>
<td>5%</td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td>10%</td>
</tr>
<tr>
<td>North America</td>
<td>41%</td>
</tr>
<tr>
<td>Europe</td>
<td>44%</td>
</tr>
<tr>
<td>Others</td>
<td>5%</td>
</tr>
</tbody>
</table>

H1/19: €17.3 billion

SALES BY BUSINESS SEGMENT

<table>
<thead>
<tr>
<th>Business Segment</th>
<th>Sales Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresenius Vamed</td>
<td>4%</td>
</tr>
<tr>
<td>Fresenius Kabi</td>
<td>20%</td>
</tr>
<tr>
<td>Fresenius Helios</td>
<td>27%</td>
</tr>
<tr>
<td>Fresenius Medical Care</td>
<td>49%</td>
</tr>
</tbody>
</table>

H1/19: €17.3 billion
FRESENIUS SHARE / ADR

 Securities code no. 578 560
 ISIN DE0005785604
 Ticker symbol FRE
 ADR CUSIP 35804M105
 ADR Ticker symbol FSNUY
 Number of shares (June 30, 2019) 556,842,018
 Market capitalization (June 30, 2019) €26.6 billion

RELATIVE SHARE PRICE PERFORMANCE

FRESENIUS SHARE VS. DAX

DAX
Fresenius share

90
100
110
120
130
30.06.2019
31.05.2019
30.04.2019
31.03.2019
28.02.2019
31.01.2019
31.12.2018

SHARE PERFORMANCE 1

2nd quarter
1 year
3 years
5 years
10 years

-4%
-31%
-28%
+31%
+323%

1 Effective date/closing price: March 31, 2019

FRESENIUS GROUP: FINANCING MIX

Schuldschein Loans 7%
Commercial Paper 9%
Other financial liabilities 10%
Syndicated loans 22%
Total B/S debt: €21,106 million 1

1 Adjusted for IFRS 16 effect

DEVELOPMENT SHARE DIVIDENDS IN €

FRESENIUS SHARE / ADR


0.25 0.29 0.32 0.37 0.42 0.44 0.55 0.62 0.75 0.80

GROUP OUTLOOK 2019

E€m (except otherwise stated)
FY/18 Base 1
Targets 2019
Sales, growth (cc) 33,009 1 4% – 7% 1
Net income 1, growth (cc) 1,872 2 ~ 0% 2

1 On a comparable basis: FY/18 adjusted for gain related to divestitures of Care Coordination activities at FMC (H1/18); FY/19: adjusted for IFRS 16 effect
2 On a comparable basis: FY/18 before special items and adjusted for gain related to divestitures of Care Coordination activities at FMC (H1/18);
FY/19: before special items (transaction-related expenses, expenses associated with the cost optimization program at FMC, revaluations of biosimilars contingent liabilities); including operating results of NxStage, adjusted for IFRS 16 effect; adjusted for gain related to divestitures of Care Coordination activities at FMC

FINANCIAL CALENDAR

Dates
Report on 1st–3rd quarter 2019 October 29, 2019
Annual General Meeting, Frankfurt am Main May 20, 2020
Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi
Senior Vice President
Telephone: +49 61 72 6 08-24 85
Investor Relations
Telefax: +49 61 72 6 08-24 88
Follow us on twitter and linkedin

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25</td>
<td>0.29</td>
<td>0.32</td>
<td>0.37</td>
<td>0.42</td>
<td>0.44</td>
<td>0.55</td>
<td>0.62</td>
<td>0.75</td>
<td>0.80</td>
</tr>
</tbody>
</table>

CONTACT

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi
Senior Vice President
Telephone: +49 61 72 6 08-24 85
Investor Relations
Telefax: +49 61 72 6 08-24 88
Follow us on twitter and linkedin

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25</td>
<td>0.29</td>
<td>0.32</td>
<td>0.37</td>
<td>0.42</td>
<td>0.44</td>
<td>0.55</td>
<td>0.62</td>
<td>0.75</td>
<td>0.80</td>
</tr>
</tbody>
</table>